Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharmacia settles Xalatan, Travatan patent cases

Executive Summary

Allergan will pay Pharmacia $120 mil. plus Lumigan product royalties "for a specified time" in Pharmacia Xalatan patent infringement suit settlement, Pharmacia says Oct. 25. Allergan will retain rights to worldwide commercialization of Lumigan. Allergan filed suit against Pharmacia March 1 seeking ruling that Lumigan did not infringe Xalatan patents (1"The Pink Sheet" March 19, p. 29). Pharmacia has also settled with Alcon over patent dispute involving Alcon's Travatan.Alcon will pay royalties on "past and future sales" of Travatan in return for continued unrestricted global marketing, Pharmacia says....
Advertisement

Related Content

Travatan and Lumigan Join Prostaglandin Class With March 16 Approval
Travatan and Lumigan Join Prostaglandin Class With March 16 Approval
Advertisement
UsernamePublicRestriction

Register

PS040697

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel